A 52-year-old man with type 2 diabetes and hypertension presents with LDL-C 180 mg/dL despite 6 weeks of atorvastatin 40 mg daily. His liver function tests and creatine kinase are normal. He reports no muscle pain or weakness. What is the most appropriate next step in management?

## Management of Statin-Resistant Hypercholesterolaemia **Key Point:** When LDL-C remains above goal after 6 weeks of moderate-intensity statin therapy with good adherence and normal safety parameters, the next step is to intensify statin therapy and add a non-statin agent. ### Rationale for Correct Answer This patient has inadequate LDL-C lowering on atorvastatin 40 mg. The appropriate escalation strategy is: 1. **Uptitrate statin to high-intensity dose** (atorvastatin 80 mg or rosuvastatin 40 mg) 2. **Add ezetimibe 10 mg daily** — a cholesterol absorption inhibitor that reduces LDL-C by an additional 15–20% when combined with statins This combination achieves synergistic LDL-C reduction and is guideline-recommended for patients not at goal on moderate-intensity statin monotherapy [cite:Harrison 21e Ch 395]. ### Why This Approach? - **Ezetimibe mechanism:** Blocks Niemann-Pick C1-like 1 (NPC1L1) protein in intestinal epithelium, reducing cholesterol absorption - **Additive effect:** Statins reduce hepatic synthesis; ezetimibe reduces intestinal absorption — complementary targets - **Safety:** No increased myopathy risk when combined; liver and muscle monitoring unchanged - **Cost-effective:** Ezetimibe is inexpensive and well-tolerated **High-Yield:** Ezetimibe + statin is the standard second-line combination before considering PCSK9 inhibitors or inclisiran. ### Treatment Intensification Algorithm ```mermaid flowchart TD A[LDL-C above goal on moderate-intensity statin]:::outcome --> B{Adherence & tolerability OK?}:::decision B -->|Yes| C[Uptitrate statin to high-intensity]:::action C --> D[Add ezetimibe 10 mg daily]:::action D --> E[Recheck LDL-C at 4–6 weeks]:::action E --> F{At goal?}:::decision F -->|Yes| G[Continue combination]:::outcome F -->|No| H[Consider PCSK9i or inclisiran]:::action B -->|No| I[Assess barriers, optimize adherence]:::action ``` **Clinical Pearl:** Always verify adherence and rule out secondary causes (hypothyroidism, nephrotic syndrome, medication interactions) before escalating therapy.